Anrikefon

安瑞克芬

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameAnrikefon
Drug Alias Name思舒静HSK-21542
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKappa opioid receptor agonists
TargetsKappa opioid receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingPharmaceutical aidsChronic Pain +[15] 
Global Approved IndicationsPain, PostoperativePruritus
Approved Indications in ChinaPain, PostoperativePruritus
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/13
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSichuan Haisco Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTibet Haisco Pharmaceutical Co LtdTianjin Medical University Cancer Institute And HospitalThe First Affiliated Hospital Of Wenzhou Medical University +[6] 
Inactive CompaniesN/A
Active IndicationsChemotherapy-induced nausea and vomitingChronic PainPostoperative Nausea and Vomiting +[12] 
Inactive IndicationsPharmaceutical aidsAcute PainPain

Other Information

ATC CodeN/A
Related LinksN/A